Rocuronium
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (January 2008) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
|
|
Rocuronium
|
|
| Systematic (IUPAC) name | |
| [3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16- (1-prop-2-enyl-2,3,4,5-tetrahydropyrrol- 1-yl)- 2,3,4,5,6,7,8,9,11,12,14,15,16,17- tetradecahydro-1H-cyclopenta[a] phenanthren- 17-yl] acetate | |
| Identifiers | |
| CAS number | |
| ATC code | M03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C32H53N2O4+ |
| Mol. mass | 529.774 g/mol |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | ~30% |
| Metabolism | some de-acetylation |
| Half life | 66–80 minutes |
| Excretion | Unchanged, in bile and urine |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Rocuronium is an aminosteroid non-depolarizing (that is, it does not cause initial stimulation of muscles before weakening them) neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
It is a more recent member of a family of similar drugs. It has rapid onset, and intermediate duration of action. It is marketed under the trade name of Zemuron in the United States and Esmeron in most other countries.
There is considered to be some risk of allergic reaction to the drug in occasional patients, but, a similar incidence of allergic reactions has been observed by using other members of the drug class (non-depolarizing neuromuscular blocking drugs). The drug is commonly used in modern anaesthesia.
The γ-cyclodextrin derivative sugammadex has been recently introduced as a novel agent to reverse the action of rocuronium.
|
|||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
